AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Black Diamond Therapeutics reports silevertinib's 60% ORR in NSCLC patients.
ByAinvest
Wednesday, Dec 3, 2025 7:07 am ET1min read
Black Diamond Therapeutics reports silevertinib's robust anti-tumor activity in 43 1L NSCLC patients with 35 different non-classical EGFR mutations, with an ORR of 60% and a CNS response rate of 86%. No new safety signals have been observed to date. PFS data for 1L NSCLC patients is expected in Q2 2026. The company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet